Global vaccine reach IVI operates across multiple regions with offices in Seoul, Europe, Africa, and partnerships in Asia and the Americas, indicating a broad footprint and potential for multi-regional partnerships, distribution potential, and joint ventures to scale vaccine delivery.

Strategic partnerships Recent collaborations with StiRx, The Bio Investments Group, TriLink BioTechnologies, and Kenyan research institutions suggest a strong openness to co-development, technology transfer, and co-funding opportunities for new vaccine platforms and formulations.

Low-cost vaccines IVI has a track record of developing affordable vaccines, including the world’s first low-cost oral cholera vaccine and a WHO-prequalified typhoid conjugate vaccine, presenting sales angles to governments and NGOs seeking cost-effective immunization solutions.

Funding and scale With substantial annual revenue and state funding from multiple governments, IVI demonstrates financial capacity and credibility to co-invest in large-scale vaccine programs, manufacturing initiatives, and regional health system strengthening projects.

Public health alignment IVI’s focus on vaccines addressing diseases prevalent in low- and middle-income countries, WHO engagement, and participation in global health dialogues positions it as a qualified partner for funding opportunities, clinical trial networks, and vaccine access initiatives aligned with donor priorities.